Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $18.63 Average PT from Analysts
Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Free Report) has earned an average recommendation of “Buy” from the ten brokerages that are covering the company, Marketbeat reports. Seven analysts have rated the stock with a buy recommendation and three have issued a strong buy recommendation on the company. The average 1-year price objective among analysts that […]
Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Free Report) has earned an average recommendation of “Buy” from the ten brokerages that are covering the company, Marketbeat reports. Seven analysts have rated the stock with a buy recommendation and three have issued a strong buy recommendation on the company. The average 1-year price objective among analysts that […]
